Abstract:INTRODUCTION:Components of the metabolic syndrome are highly prevalent in chronic kidney disease (CKD) patients--some of which paradoxically appear to predict an improved outcome in this population. We hypothesized that the circulating calcification inhibitor fetuin-A/AHSG, which is also a natural inhibitor of the tyrosine kinase insulin receptor, could be one factor explaining the association between increased fat mass and a survival advantage in CKD and thus conducted an explorational study to provide preliminary data to support further research into this hypothesis. PATIENTS AND METHODS:In a cross-sectional study, we evaluated 198 CKD stage 5 patients (GFR 6.8 +/- 0.2 ml/min; 62% males, mean age 52 +/- 1 years) close to the start of renal replacement therapy. We studied circulating AHSG (ELISA) and two common functional AHSG gene polymorphisms (at amino acids Thr248Met (C-T) and Thr256Ser (C-G) using Pyrosequencing) and related these to multiple components of the metabolic syndrome. RESULTS:Median circulating AHSG was lower (p < 0.01) in type-2 (0.22 g/l) and type-1 (0.16 g/l) diabetics as compared to non-diabetic CKD-5 patients (0.24 g/l). AHSG correlated with both total and truncal fat mass in type-2 diabetics (rho 0.37 and 0.39; p < 0.001, respectively), but not in type-1 diabetics or non-diabetics. Both SNPs significantly influenced circulating levels of AHSG, and were also associated with significant differences in serum triglycerides and HDL cholesterol. Furthermore, there were significant differences in the prevalence of metabolic syndrome criteria between the AHSG Thr256Ser (C-G) genotype groups, with a more atherogenic lipid profile in AHSG high producers (Thr/Thr homozygotes). In multivariate analysis, the association between circulating AHSG and fat mass remained significant also after adjustment for age, gender, inflammation (CRP >10 mg/l), and AHSG genotype. CONCLUSIONS:The present, explorational, study supports further, mechanistic, studies into a physiological link between AHSG and body fat mass in patients with CKD. As we observed an association between higher fat mass and elevated AHSG levels, these preliminary results may form the basis of further study to establish if the observed associations may be one reason why obesity has been reported to constitute a survival advantage in CKD.

Increased Circulating Full-Length Betatrophin Levels in Drug-Naïve Metabolic Syndrome

Serum betatrophin level increased in subjects with metabolic syndrome: a case-control study

Circulating Betatrophin Levels Are Increased in Patients with Type 2 Diabetes and Associated with Insulin Resistance

Serum betatrophin level increased in subjects with nonalcoholic fatty liver disease

Aumento Del Nivel De Betatrofina En Suero En Sujetos Con Síndrome Metabólico: Estudio De Casos Y Controles

Clinical Significance and Serum Concentration of Inflammatory Factor and Adiponectin in Children with Metabolism Syndrome

Betatrophin Provides a New Insight into Diabetes Treatment and Lipid Metabolism (Review).

[Elevated serum levels of betatrophin in patients with polycystic ovary syndrome and the influential factors]

Relationship of Serum Betatrophin with Nonalcoholic Fatty Liver in a Chinese Population

Sensitivity to thyroid hormone and risk of components of metabolic syndrome in a Chinese euthyroid population

Plasma Signature Metabolites of Dietary Fat Intake Characterize Associations with Prevalent Metabolic Syndrome

Betatrophin and Insulin Resistance

Emerging regulation and function of betatrophin

A Non-invasive Model for Detection of Undiagnosed Metabolic Syndrome in School Children and Adolescents

The Association Between Serum Thyrotropin Within the Reference Range and Metabolic Syndrome in a Community-Based Chinese Population.

Serum betatrophin levels are significantly increased in obese patients compared to lean patients regardless to the presence of PCOS

Serum Fetuin-a is Correlated with Metabolic Syndrome in Middle-Aged and Elderly Chinese.

Is Fetuin-A/Alpha 2-Heremans-schmid Glycoprotein Associated with the Metabolic Syndrome in Patients with Chronic Kidney Disease?

Relationship between adipose cytokines and metabolic syndrome in newly diagnosed type 2 diabetes mellitus patients

The relationship between serum thyrotropin and components of metabolic syndrome.

Perirenal Fat Thickness: A Surrogate Marker for Metabolic Syndrome in Chinese Newly Diagnosed Type 2 Diabetes